GSEA analysis revealed that this 37-gene signature was significantly associated with the GSK-J4 treatment (Supplementary Fig. 12b, c), suggesting that KDM6B inhibition consequently downregulates the functions of PRC2, leading to the induction of tumor-suppressive program repressed by EZH2. Here, EZH2 is linked to neoplasm.